Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01651039 · ClinicalTrials.gov registry record · Phase 2

Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)

A Phase 2 study of Multiple Myeloma, sponsored by Ajai Chari.

Completed
Registry status
Phase 2
Development phase
32
Enrollment target
1
Study location

NCT01651039: Completed Phase 2 study of Multiple Myeloma, sponsored by Ajai Chari.

NCT01651039 is a Phase 2 study of Multiple Myeloma that has completed, run by Ajai Chari. The registered enrollment target is 32 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01651039, a Phase 2 study of Multiple Myeloma, has completed, sponsored by Ajai Chari.

COMPLETED
Registry status
Phase 2
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

The purpose of this clinical research study is to find out the effects of a drug called panobinostat (LBH589) when given to people like you with multiple myeloma in combination with the drugs lenalidomide and dexamethasone. The safety of this combination of drugs will also be studied. Your physical state, changes in the state of your multiple myeloma, and laboratory findings taken while on-study will help us decide if panobinostat combined with dexamethasone and lenalidomide is safe and effective. This goal of this study therefore is to determine the activity of the combination of panobinostat thrice weekly every other week, lenalidomide, and weekly dexamethasone in a similar group of subjects. The doses of lenalidomide and dexamethasone will be that which is approved by the FDA for multiple myeloma and you will take each drug at a specific frequency over a 4 week (28 day) period. This period is called a "study cycle".

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Lenalidomide
  • DRUG Panobinostat

Study Locations (1)

New York

  • Icahn School of Medicine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2012-07
Est. Completion 2016-12-21
Phase Phase 2

Sponsor

Ajai Chari

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01651039

The ClinicalTrials.gov registry entry for NCT01651039 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower). The listed sponsor is Ajai Chari, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.

NCT01651039 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01651039 about?

NCT01651039 is a clinical study titled "Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)". The purpose of this clinical research study is to find out the effects of a drug called panobinostat (LBH589) when given to people like you with multiple myeloma in combination with the drugs lenalidomide and dexamethasone. The safety of this combination of drugs will also be studied. Your physical ...

What is the current status of trial NCT01651039?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2012-07. Estimated completion is 2016-12-21.

What conditions does trial NCT01651039 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT01651039?

The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Panobinostat (DRUG).

Who is sponsoring clinical trial NCT01651039?

This trial is sponsored by Ajai Chari, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01651039 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.